Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: GlobalData
$250.00
Provider: MarketLine (a Datamonitor Company)
$50.00
Provider: Wright Reports
$472.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Sartorius Stedim Biotech SA Confirms FY 2013 EBITDA Margin and Sales Revenue Guidance


Sunday, 20 Oct 2013 08:00pm EDT 

Sartorius Stedim Biotech SA announced that it confirmed its earnings forecast for fiscal year 2013. This forecast projects an increase in the Group's underlying EBITDA margin to around 19.5% based on constant currencies (cc). Consolidated sales revenue is expected to increase approx. 7% in constant currencies, within the growth corridor of 6% to 9% communicated at the beginning of the year, but not quite reach the upper half of this corridor as forecasted at mid-year. The Company reported fiscal year 2012 revenue of EUR 544 million. According to I/B/E/S estimates, analysts on average are expecting the Company to report fiscal year 2013 revenue of EUR 602.63 

Company Quote

137.2
0.75 +0.55%
23 Apr 2014